4/A: BiomX Inc. Director Corrects Error in Form 4 Filing Regarding Option Acquisition

A BiomX Inc. director, Jesse Goodman, filed an amended Form 4 to correct an administrative error in the reporting of derivative securities acquired.

Summary

• Jesse Goodman, a director of BiomX Inc., filed an amendment to a previously submitted Form 4.
• The amendment corrects an error in Table II, Column 5, where the number of derivative securities acquired was incorrectly reported as disposed of (D) instead of acquired (A).
• The transaction involves options to purchase 17,600 shares of BiomX Inc. common stock at an exercise price of $0.538.
• These options vest over four years, with 25% vesting on April 14, 2026, and the remainder vesting in 12 equal quarterly installments over three years.
• No other changes were made to the originally filed Form 4.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't indicate any fundamental issues with the company, so the sentiment is neutral to slightly positive due to the transparency.

Industry Context

Form 4 filings are standard practice for company insiders (directors, officers, and 10% owners) to report transactions in their company's securities to the SEC, ensuring transparency and preventing insider trading.

Key Dates

Keywords

Form 4, Amendment, BiomX Inc., Director, Jesse Goodman, Options, Derivative Securities, Beneficial Ownership, Vesting